Invivyd (IVVD) Cash from Investing Activities (2021 - 2025)
Invivyd's (IVVD) quarterly Cash from Investing Activities came in at -$11000.0 in Q2 2025, up 92.36% quarter-over-quarter from -$144000.0 in Q1 2025.
Analysis
Invivyd (IVVD) Cash from Investing Activities (2021 - 2025) Analysis & Trends
Invivyd (IVVD) has reported Cash from Investing Activities for 5 consecutive years, with -$11000.0 the latest figure, recorded in Q2 2025.
- For the quarter ending Q2 2025, Cash from Investing Activities changed N/A year-over-year to -$11000.0; the trailing twelve-month figure through Dec 2025 stood at -$155000.0 (down 10.71% YoY), and the FY2025 full-year result was -$155000.0, down 10.71% from the prior year.
- Cash from Investing Activities grew to -$11000.0 in Q2 2025 per IVVD's latest filing, from -$144000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $137.9 million in Q4 2021 and bottomed at -$188.6 million in Q3 2021.
- Historically, Cash from Investing Activities has averaged -$65933.3 across 5 years, with a median of -$5000.0 in 2024.
- The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities slumped 200.65% in 2022, then jumped 191835.29% in 2023.
- Over 5 years, Cash from Investing Activities stood at $137.9 million in 2021, then plunged by 200.65% to -$138.8 million in 2022, then jumped by 156.13% to $77.9 million in 2023, then slumped by 99.99% to $5000.0 in 2024, then tumbled by 320.0% to -$11000.0 in 2025.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$11000.0, -$144000.0, and $5000.0 for Q2 2025, Q1 2025, and Q4 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | -569.00 Mn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -10.35 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | -45.80 Mn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | -92.70 Mn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 329.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -3.84 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Invivyd | 244.65 Mn | 84.57 Mn | 13.01 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | -11,000.00 |
| Mar 31, 2025 | -144,000.00 |
| Dec 31, 2024 | 5,000.00 |
| Sep 30, 2024 | -5,000.00 |
| Mar 31, 2024 | -140,000.00 |
| Dec 31, 2023 | 77.92 Mn |
| Sep 30, 2023 | 95.14 Mn |
| Jun 30, 2023 | 32.60 Mn |
| Mar 31, 2023 | 75.04 Mn |
| Dec 31, 2022 | -138.81 Mn |
| Sep 30, 2022 | -140.84 Mn |
| Jun 30, 2022 | -17,000.00 |
| Mar 31, 2022 | 49.00 Mn |
| Dec 31, 2021 | 137.92 Mn |
| Sep 30, 2021 | -188.63 Mn |